Tissue Repair & Recovery

Pentadeca Arginate (PDA)

Also known as PDA · BPC-157 arginate · Pentadecapeptide arginate salt

AnecdotalSubcutaneous injectionIntramuscular injectionNot FDA-approved for any indication; no separate approval or trial base. Available only through compounding/research channels and subject to the same regulatory scrutiny as BPC-157.

Pentadeca arginate is a pentadecapeptide sharing the BPC-157 amino-acid sequence but formulated as an arginate salt rather than the acetate salt. It is sold as a tissue-repair product with claimed effects on angiogenesis, collagen synthesis, and inflammation extrapolated from BPC-157 research. Importantly, PDA has not been studied as a distinct molecule in published peer-reviewed human or animal efficacy trials, and stability claims originate largely from vendor materials rather than the scientific literature.

Studied / used for

Sold for soft-tissue, tendon, and ligament healing, with claims extrapolated from BPC-157 research
Used in injury-recovery settings without distinct trial support
Associated with claimed angiogenic and anti-inflammatory effects not yet directly studied

Commonly reported side effects

Injection-site reactions
Minimal independent human safety data
Safety profile inferred from BPC-157 rather than direct study

Anecdotal. Limited formal evidence; reports are largely anecdotal. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds